Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Unknown 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 43INDUSTRY 18OTHER_GOV 4UNKNOWN 1NIH 1NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Platinum Compounds × Clear all
NCT07629817 2026-06-05

HCHTOG2603

Henan Cancer Hospital

Phase 3 Not yet recruiting
1,044 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07320105 2026-01-06

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Fujian Cancer Hospital

Phase 4 Recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Henan Cancer Hospital

Phase 2 Unknown
132 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Fujian Cancer Hospital

Phase 2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡